top of page


Follow us on LinkedIn and never miss the latest updates.


EraCal selected to TOP Swiss Biotech Startups 2023

7. September 2023

EraCal selected to top 100 Swiss Startup in 2023 – position 20 this year. Thank you for all your support.


Nestlé Health Science enters into Research Collaboration with EraCal Therapeutics

16. February 2023

Read the full press release here.


EraCal selected to TOP Swiss Biotech Startups 2022

7. September 2022

EraCal selected to top 100 Swiss Startup in 2022 – position 29 this year. Thank you for all your support.


How to fight obesity and other metabolic disorders—swimmingly

7. June 2022

This article by Nature Research describes EraCal differentiated phenotypic strategy to measure food intake, energy expenditure, among other phenotypes at scale targeting cardiometabolic diseases.  


EraCal enters into Research Collaboration with Novo Nordisk

17. January 2022

Read the full press release here.


Greg Hamilton and Jean-Michel Cossery join EraCal as independent board members

30. December 2021

EraCal Therapeutics appoints Jean-Michel Cossery and Greg Hamilton to its Board of Directors. Thank you for your leadership.


EraCal selected to TOP Swiss Biotech Startups 2021

8. September 2021

EraCal selected to top 100 Swiss Startup in 2021 – position 34 this year. Thank you for all your support.


EraCal launches a program targeting a novel class of appetite-stimulants

25. March 2021

The University of Zurich and EraCal start a new joint-project by applying the zebrafish technology towards appetite-stimulants. The program is part of the Swiss Innovation Power framework led by Innosuisse.


EraCal expands operations and moves to Bio-Technopark Schlieren Zurich, Switzerland

1. February 2021


EraCal featured among Switzerland's promising startups

9. September 2020

EraCal selected to the top100 Swiss StartUps for the first time in 2020. Thank you for all your support.

The Spinoff Prize_Finalist 2020_2_Whitne

Nature and Merck KGaA highlight EraCal’s effort towards a long-term obesity therapy

30. June 2020

Thank you for depicting the advantages of EraCal’s phenotypic platform to identify selective and potent appetite suppressors. We are honored to be selected as a Spinoff prize finalist.


EraCal is a member of the Swiss National Startup Team 2020

22. April 2020

The Swiss Life Science National Team selected EraCal for its 2020 class. Thank you for recognizing our entrepreneurial ambitions.


IMD and EraCal join forces

13. December 2019

EraCal selected as an entrepreneurial showcase for IMD‘s Executive MBA class 2020.

IMG_20190924_174407 (2)_edited.jpg

EraCal closed oversubscribed seed round

16. October 2019

EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.


EraCal in the news of the University of Zurich

10. September 2019

The UZH news (English Deutsch) tells our initial StartUp journey towards a new therapeutic solution for obesity.


EraCal wins MIT life science angels award

28. August 2019

EraCal won the MIT life science angels award and enjoyed thrilling days in Boston. Thank you for recognizing our creative science strategy and our global mission!


EraCal is a »venture» finalist

16. May 2019

EraCal Therapeutics is among the top 10 in the “Health & Nutrition” vertical of the  »venture» business plan competition 2019. »venture» is Switzerland’s leading startup contest for entrepreneurs with high-tech business ideas.


EraCal wins venturekick

31. January 2019

The venturekick jury selected EraCal Therapeutics Ltd. as a top Swiss start-up. Thank you very much for your continuing support of our vision!

EraCal in the scientific news

31. October 2018

Articles in Science Advance and the news of the University of Zurich (English Deutsch) describe part of our drug discovery strategy and its power for translational research.

bottom of page